Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kura Oncology (NQ: KURA )

16.88 +0.16 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology

< Previous 1 2 3 4 Next >
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
KURA Stock Earnings: Kura Oncology Beats EPS for Q2 2024
KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position. 
Via InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
2 Incredible Growth Stocks to Buy Hand Over Fist
These two healthcare growth stocks could have a lot more room to run. 
Via The Motley Fool
Kura Oncology Inc. (NASDAQ: KURA) is a Stock Spotlight on 3/6
Via Investor Brand Network
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024
KURA stock results show that Kura Oncology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Kura Oncology: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Earnings Outlook For Kura Oncology
Via Benzinga
Kura Oncology Inc. (NASDAQ: KURA) Near the Top of Equities by Percentage Gain on 1/24
Via Investor Brand Network
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Kura Makes Good On Its $150 Million Infusion And Shoots Up Another 15%
The company just released promising results for its acute myeloid leukemia treatment. 
Via Investor's Business Daily
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales 
Via Benzinga
A Preview Of Kura Oncology's Earnings
Via Benzinga
Analyst Expectations for Kura Oncology's Future
Via Benzinga
Why Cancer-Drug Developer Kura Oncology Stock Is Up
Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all... 
Via Benzinga
General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Edges Lower; US Composite PMI Rises In January
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
Latest surge in Kura Oncology shares with a $150 million private placement announcement. Cash runway extended into 2027. 
Via Benzinga
Textron Posts Upbeat Earnings, Joins ASML, Progressive And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Wednesday. Shares of Textron Inc. (NYSE: TXT) rose during Wednesday’s session following upbeat quarterly earnings. 
Via Benzinga
Topics Stocks
Exposures US Equities
Kura Oncology Rockets 39% Before Unveiling Cancer Drug Test Results — Here's Why
Kura Oncology is still a week out from unveiling the results for an AML drug. But shares soared Wednesday. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst
Mizuho initiated coverage on Kura Oncology Inc (NASDAQ: KURA), spotlighting the potential of ziftomenib as a first-in-class treatment for relapsed/refractory (r/r) NPM1-m acute myeloid leukemia... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Kura Oncology's Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients
Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is... 
Via Benzinga
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP® Technology
Allarity Therapeutics (NASDAQ: ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therapies coupled with companion diagnostics. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.